| scholarly article | Q13442814 |
| P50 | author | Andreas von Deimling | Q40381084 |
| P2093 | author name string | Mingzhao Xing | |
| Xiaoli Liu | |||
| Guojun Wu | |||
| Christian Hartmann | |||
| Yuan Shan | |||
| P2860 | cites work | Highly recurrent TERT promoter mutations in human melanoma | Q29614798 |
| TERT promoter mutations in familial and sporadic melanoma | Q29614920 | ||
| TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal | Q36762656 | ||
| Telomerase RNA biosynthesis and processing | Q38060194 | ||
| Telomerase and the search for the end of cancer | Q38068624 | ||
| P433 | issue | 10 | |
| P921 | main subject | bladder cancer | Q504775 |
| P1104 | number of pages | 2 | |
| P304 | page(s) | 1637-1638 | |
| P577 | publication date | 2013-04-19 | |
| P1433 | published in | Cell Cycle | Q1254166 |
| P1476 | title | Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma | |
| P478 | volume | 12 |
| Q91653586 | A Glioblastoma Genomics Primer for Clinicians |
| Q38849194 | A second chance for telomerase reverse transcriptase in anticancer immunotherapy |
| Q26773514 | Advances in the treatment of newly diagnosed glioblastoma |
| Q35753087 | Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis. |
| Q35985808 | BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. |
| Q26738705 | Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications |
| Q36560914 | Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation |
| Q37687028 | Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies |
| Q40857012 | Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness |
| Q34827556 | Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. |
| Q37687183 | Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up |
| Q27008242 | Distinct genetic alterations in small cell carcinoma from different anatomic sites |
| Q48915503 | Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system |
| Q92664567 | Diverse regulatory manners of human telomerase reverse transcriptase |
| Q37149600 | Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. |
| Q37624069 | Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. |
| Q34469034 | High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins |
| Q27852353 | Highly prevalent TERT promoter mutations in aggressive thyroid cancers |
| Q51415479 | In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation. |
| Q30457044 | Inhibition of telomerase recruitment and cancer cell death |
| Q38235572 | Isocitrate dehydrogenase 1 and 2 mutations in gliomas. |
| Q37449688 | Lack of TERT Promoter Mutations in Human B-Cell Non-Hodgkin Lymphoma |
| Q43540329 | Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers |
| Q47702648 | Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms |
| Q52727349 | Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. |
| Q92761632 | Microvascularity detection and quantification in glioma: a novel deep-learning-based framework |
| Q39440917 | Molecular Pathogenesis of Liver Cancer |
| Q35930911 | Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer |
| Q48238570 | Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. |
| Q33688915 | Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas |
| Q48138460 | Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients. |
| Q89666640 | Practice of the New Integrated Molecular Diagnostics in Gliomas: Experiences and New Findings in a Single Chinese Center |
| Q37221898 | Prognostic Stratification of GBMs Using Combinatorial Assessment of IDH1 Mutation, MGMT Promoter Methylation, and TERT Mutation Status: Experience from a Tertiary Care Center in India |
| Q93046820 | Prognostic significance of hTERT (human telomerase reverse transcriptase) promoter region mutations C228T and C250T for overall survival in spinal chordomas |
| Q38164307 | Regulatory variation: an emerging vantage point for cancer biology |
| Q43274590 | Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma |
| Q92596277 | Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer |
| Q89551068 | TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients |
| Q40858851 | TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas. |
| Q33414576 | TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities |
| Q38774845 | TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract |
| Q35151119 | TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer |
| Q28390726 | TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma |
| Q35833084 | TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. |
| Q33682388 | TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer |
| Q35068013 | TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR |
| Q34499685 | TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations |
| Q33688439 | TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas |
| Q26770808 | TERT promoter mutations in thyroid cancer |
| Q60917015 | Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma |
| Q38232447 | Telomerase promoter mutations in cancer: an emerging molecular biomarker? |
| Q40199208 | Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change |
| Q46754264 | Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients |
| Q55443450 | Telomere Maintenance Mechanisms in Cancer. |
| Q90596932 | The Solo Play of TERT Promoter Mutations |
| Q38349169 | The evolving molecular genetics of low-grade glioma |
| Q55377785 | The expression of telomere-related proteins and DNA damage response and their association with telomere length in colorectal cancer in Saudi patients. |
| Q41542800 | The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas |
| Q37295512 | The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients |
| Q38903424 | The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism. |
| Q26781886 | The search for cis-regulatory driver mutations in cancer genomes |
| Q90744618 | Therapeutic Targets in Telomerase and Telomere Biology of Cancers |
| Q58796314 | Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates |
| Q50072573 | Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G>A/T Mutation |
| Q26739925 | Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene |
| Q47185839 | Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations |
| Q38760235 | Understanding TERT Promoter Mutations: A Common Path to Immortality. |
| Q92539491 | Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study |
Search more.